{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-25-000027","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.376007+00:00","generated_at":"2026-05-21T12:34:01.128349+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexicon Q1 net loss narrows to $25.3M; Novo Nordisk license for LX9851, pipeline progress","bullets":["Net loss of $25.3M ($0.07/sh) vs $48.4M ($0.20/sh) in Q1 2024; revenue $1.3M.","Cash and investments $194.8M at Mar 31, 2025, down from $238.0M at Dec 31, 2024; includes $7.5M severance.","Exclusive license to Novo Nordisk for LX9851; up to $1B milestones, $75M upfront/near-term payments plus royalties.","Phase 2b PROGRESS study of pilavapadin (DPNP) met objective; 10 mg dose identified for Phase 3.","Operating expenses down ~40% YoY as company transitions to R&D-focused."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-25-000027","json":"https://secwatch.observer/filing/0001062822-25-000027.json","markdown":"https://secwatch.observer/filing/0001062822-25-000027.md","text":"https://secwatch.observer/filing/0001062822-25-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282225000027/0001062822-25-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282225000027/lxrx-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T12:34:01.128349+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}